Skip to content

GROUP EXECUTIVE COMMITTEE

Stephen Saad (56)

Classification: Group Chief Executive

Qualifications: CA(SA), PhD (Commerce) Honoris Causa

Appointed: January 1999

Stephen is a founding shareholder of Aspen. His responsibilities include strategic positioning of Aspen as a leading multinational pharmaceutical company, global transactions, geographic expansion and product diversification of Aspen in emerging and developed markets.

Further information

Gus Attridge (60)

Classification: Deputy Group Chief Executive (Finance Director)

Qualifications: CA(SA)

Appointed: January 1999

Gus is a founding shareholder of Aspen and is responsible for the strategic and financial well-being of the Group while also identifying and pursuing appropriate corporate opportunities and global transactions that will further benefit Aspen and our stakeholders.

Further information

Sean Capazorio (55)

Classification: Group Finance Officer

Qualifications: CA(SA)

Appointed: January 1999

Sean is responsible for the Group’s finance functions across Aspen’s businesses and he also assesses business performance and identifies business improvement opportunities.

Further information

Richelle Crots (57)

Classification: Regional Chief Executive Officer, SA Commercial

Qualifications: BCom (Human Resources)

Appointed: August 2017

Richelle is responsible for the overall operations of Aspen’s South African Commercial Pharmaceutical business, including SADC countries. She provides executive leadership across this organisation, including overall strategic direction and leads new business development and opportunities.

Further information

Reginald Haman (47)

Classification: Chief Corporate Services Officer

Qualifications: MBA, PGDBA, Graduate Diploma in Company Direction

Appointed: May 2020

Reginald is responsible for managing Aspen’s cluster of Group Corporate Services functions. He also ensures the provision of efficient and effective services to the Group in accordance with business and legislative requirements. Reginald was appointed as a member of the Social & Ethics Committee on 1 September 2020.

Further information

Lorraine Hill (57)

Classification: Chief Operations Officer

Qualifications: BPharm

Appointed: January 1999

Lorraine is responsible for multiple operational areas of the business including strategic manufacturing, pharmaceutical affairs, new product development and strategic procurement. In addition, she plays an integral role in negotiation and implementation of new business initiatives for the Manufacturing business which she also represents in global transactions.

Further information

Samer Kassem (46)

Classification: Chief Executive Officer, Aspen Global Incorporated

Qualifications: CMA, CFM, CBM, MBA

Appointed: May 2008

Samer joined the Group with the responsibility of establishing the company to lead and direct its international operations. He has been integrally involved in the negotiation, completion and integration of strategic acquisitions, the setting up of the Group’s global businesses as well as the trading and supply structures to support these.

Further information

Zizipho Mmango (36)

Classification: Chief Strategic Development Officer

Qualifications: CA(SA), CFA

Appointed: May 2020

Zizipho is responsible for focusing on assessing and implementing strategic development activities for the Group such as acquisitions, disposals and collaborations. She also plays an active role in advancing business performance and value enhancement opportunities.

Further information

Stavros Nicolaou (55)

Classification: Group Senior Executive Strategic Trade

Qualifications: B.Pharm, FPS (SA), PhD (Medicine) Honoris Causa

Appointed: January 1999

Stavros plays a pivotal role in the initiation of business development opportunities and is also key to the building and maintenance of strategic relations within industry and with all of Aspen’s stakeholders.

Further information

Trevor Ziman (50)

Classification: Chief Executive Officer, Asia Pacific

Qualifications: CA(SA)

Appointed: May 2001

Trevor is responsible for the implementation of strategy and the performance delivery of Aspen’s Commercial Pharmaceutical businesses in Australasia, the Philippines, Taiwan, Malaysia and Hong Kong as well as trade into the rest of the Asia Pacific region. He plays a leading role in all transactional activity in the region.

Further information
Scroll To Top